PCSK9 and atherosclerosis: For patients diagnosed with clinical ASCVD, the proprotein convertase subtilisin-kexin type 9 inhibitors (PCSK9i) alirocumab and evolocumab were approved by the Federal Drug Administration in 2015 [113].